[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634369":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":10,"centralContacts":28,"locations":34,"responsibleParty":112,"collaborators":10,"id":114,"slug":115,"hasResults":116,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":116,"sex":122,"minAge":123,"maxAge":10,"enrollmentInfo":124,"targetDuration":10,"studyType":127,"phases":10,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":139,"whyStopped":10,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},{"fullName":5,"class":6},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"MONO 177Lu",null,"Patients treated with PRRT using ¹⁷⁷Lu only.",[13],"Radiation: Peptide Receptor Radionuclide Therapy (PRRT)",{"label":15,"type":10,"description":16,"interventionNames":17},"MONO 90Y","Patients treated with PRRT using ⁹⁰Y only.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"TANDEM 177Lu + 90Y","Patients treated with PRRT using a combination (sequential or concomitant) of ¹⁷⁷Lu and ⁹⁰Y.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"RADIATION","Peptide Receptor Radionuclide Therapy (PRRT)","PRRT with radiolabeled somatostatin analogues (¹⁷⁷Lu and\u002For ⁹⁰Y), according to clinical practice.",[9,15,19],[29],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Angelina Filice, MD","CONTACT","0522 296313","angelina.filice@ausl.re.it",[35,46,54,62,70,78,83,91,99,104],{"facility":36,"status":10,"city":37,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":10},"Policlinico di Bari","Bari","Italy","IT",{"type":41,"coordinates":42},"Point",[43,44],16.86982,41.12066,{"lat":44,"lon":43},{"facility":47,"status":10,"city":48,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":49,"geoPoint":53,"contacts":10},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","Bologna",{"type":41,"coordinates":50},[51,52],11.33875,44.49381,{"lat":52,"lon":51},{"facility":55,"status":10,"city":56,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":57,"geoPoint":61,"contacts":10},"Azienda Ospedaliero-Universitaria di Ferrara","Ferrara",{"type":41,"coordinates":58},[59,60],11.62057,44.83804,{"lat":60,"lon":59},{"facility":63,"status":10,"city":64,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":65,"geoPoint":69,"contacts":10},"Irst Irccs","Meldola",{"type":41,"coordinates":66},[67,68],12.0626,44.12775,{"lat":68,"lon":67},{"facility":71,"status":10,"city":72,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":73,"geoPoint":77,"contacts":10},"Fondazione IRCCS Istituto Nazionale dei Tumori di Milano","Milan",{"type":41,"coordinates":74},[75,76],12.59836,42.78235,{"lat":76,"lon":75},{"facility":79,"status":10,"city":72,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":80,"geoPoint":82,"contacts":10},"Istituto Europeo di Oncologia",{"type":41,"coordinates":81},[75,76],{"lat":76,"lon":75},{"facility":84,"status":10,"city":85,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":86,"geoPoint":90,"contacts":10},"Azienda Ospedaliero-Universitaria Policlinico di Modena","Modena",{"type":41,"coordinates":87},[88,89],10.92539,44.64783,{"lat":89,"lon":88},{"facility":92,"status":10,"city":93,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":94,"geoPoint":98,"contacts":10},"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","Naples",{"type":41,"coordinates":95},[96,97],14.26811,40.85216,{"lat":97,"lon":96},{"facility":100,"status":10,"city":93,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":101,"geoPoint":103,"contacts":10},"Università degli Studi di Napoli Federico II",{"type":41,"coordinates":102},[96,97],{"lat":97,"lon":96},{"facility":105,"status":10,"city":106,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":107,"geoPoint":111,"contacts":10},"Azienda USL IRCCS di Reggio Emilia","Reggio Emilia",{"type":41,"coordinates":108},[109,110],10.63125,44.69825,{"lat":110,"lon":109},{"type":113,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100634369","italian-multicenter-experience-with-radioreceptor-assisted-therapy-prrt-100634369",false,"NCT07538791","Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)","Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT) in Pheochromocytomas and Paragangliomas: a Retrospective Analysis","PRRT-PGL-PHEO","Inclusion Criteria:\n\n* Documented diagnosis of pheochromocytoma or paraganglioma (PPGL) (sporadic or hereditary forms) with unresectable or metastatic disease.\n* Treatment with peptide receptor radionuclide therapy (PRRT) administered with ⁷⁷Lu and\u002For ⁹⁰Y (including combination regimens), with t0 (first PRRT administration) between January 1, 2000 and February 28, 2024.\n* Availability of essential data required by the protocol to document exposure (PRRT) and outcomes, including: PRRT start date (t0) and treatment details (radioisotope(s), number of cycles and\u002For cycles actually administered, intervals when available), At least one post-treatment evaluation suitable for determining disease control rate (DCR) (morphological imaging by CT\u002FMRI ± functional imaging by PET\u002FCT, and available clinical data), Follow-up information suitable for determining progression-free survival (PFS) within the predefined time window.\n* Availability of follow-up up to 12 months from end of treatment (EoT), or documentation of progression and\u002For death occurring within 12 months.\n* Required data and source documents are available at the enrolling center or obtainable from other Italian centers (e.g., PRRT-administering center or centers performing imaging\u002Fevaluations) through formal data transfer agreements (e.g., DTA) in compliance with applicable regulations.\n* Privacy\u002Fconsent requirements (general framework):\n\nFor living and contactable patients, consent for personal data processing will be managed according to the requirements\u002Fassessment of the Ethics Committee.\n\nFor deceased or non-contactable patients after reasonable documented efforts, inclusion may occur without consent, as it falls under situations of \"impossibility to inform the subjects,\" in accordance with applicable regulations (Article 110 of the Italian Privacy Code and subsequent amendments), subject to Ethics Committee evaluation\u002Fopinion and implementation of appropriate safeguards.\n\nExclusion Criteria:\n\n* Patients who did not receive at least one cycle of peptide receptor radionuclide therapy (PRRT).","ALL","18 Years",{"count":125,"type":126},210,"ESTIMATED","OBSERVATIONAL","This multicenter retrospective Italian study evaluates the efficacy and safety of PRRT in patients with advanced, unresectable or metastatic pheochromocytomas and paragangliomas (PPGL). Data from \\~210 patients treated between 2000 and 2024 will be analyzed. The primary endpoint is disease control rate (DCR). Secondary endpoints include progression-free survival (PFS), overall survival (OS), and prognostic factors.",[130,131],"Pheochromocytomas","Paragangliomas",[133,134,135,136,137,138],"PPGL","PRRT","PHEO","PGL","Somatostatin receptors","Peptide Receptor Radionuclide Therapy","NOT_YET_RECRUITING","2026-04-21",{"date":142,"type":143},"2026-04-24","ACTUAL",{"date":145,"type":126},"2026-04-30",{"date":147,"type":126},"2028-04-30",{"name":5,"class":6},10]